ClinicalTrials.gg
RecruitingNCT06699342PALLIATE-AFUpdated Aug 20, 2026

Pacing of Left Bundle Branch Area and Atroventricular Node ablatIon in Patients With Symptomatic Atrial Fibrillation

An interventional study of Pacemaker implantation with Left bundle branch area pacing (LBBAP) and Atrioventricular node ablation (AVNA) in Atrial Fibrillation (AF), sponsored by Seoul National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Atrial Fibrillation by Seoul National University Hospital — 6 open to participants now, 7 under way, none of them phase 3. Atrial Fibrillation · Seoul National University Hospital.

Planned enrollment
10th of 12
50 · median 140
Started
2025
with 1 other
No phase
10 of 18
5 open now
Registered
16th of 18
by date

Among the 18 studies in Atrial Fibrillation by Seoul National University Hospital, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 with no phase, and was the 16th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

6 of the 18 studies in Atrial Fibrillation by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Atrial Fibrillation by Seoul National University Hospital, or all of them as a file.
02

Study summary

This study aimed to compare the clinical outcomes of left bundle branch area pacing combined with atrioventricular node ablation and pharmacologic treatment optimized according to guidelines in patients with symptomatic atrial fibrillation refractory or intolerant to drug therapy or catheter ablation.

Read the detailed description
  • Multicenter, randomized, open-label clinical trial
  • Randomization 1:1 fashion A randomly permuted-block randomization list was generated by computer at a central location and was stratified by center.
  • Study duration:

    1. 6 months (for primary outcome)
    2. 24 months (for secondary outcomes)
  • Study subjects number: 50 patients (25 patients per group)
  • Procedures

    • Atrioventricular node ablation after successful left bundle branch area pacing at the same procedure time.
    • Left bundle branch area pacing will be performed in all patients (using lumenless or stylet-driven lead, on the operator's discretion)
    • Atrioventricular node ablation will be performed using the quadripolar 7-Fr 3.5-mm tip ablation catheter and the use of 8.5-F sheath (SR0 or SL1, St. Jude Medical Inc., St. Paul, MN, USA) depending on the operator's experience, and if not stable or failed, a deflectable sheath (Agilis, Abbott Electrophysiology, Menlo Park, CA, USA) will be used. Repeated ablation procedures will be recommended during follow-up if regression of atrioventricular block has occurred.
    • Immediately after implant, devices were programmed to achieve the shortest QRS duration. Unipolar pacing was initially used to determine left bundle branch capture.
03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

Keywords

  • atrial fibrillation
  • left bundle branch area pacing
  • Atrioventricular node ablation
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who meet all of the following inclusion criteria 1)-6).

  1. Permanent atrial fibrillation
  2. Age ≥ 65 years
  3. or intolerant to antiarrhythmic drugs, rate control medications, or catheter ablation
  4. (NYHA) functional class II- IV
  5. > 40% (within the past 3 months)
  6. Patients with at least one of the following:

    1. HF hospitalization (defined as HF as the major reason for hospitalization or treatment for HF lasting ≥12 hours and including treatment with intravenous (IV) diuretics at a healthcare facility) within 12 months
    2. Elevated NT-proBNP (>900 pg/ml) in the 30 days prior to enrollment

Exclusion criteria

Exclusion:

Patients who meet at least one of the following exclusion criteria 1)-11).

  1. Asymptomatic atrial fibrillation
  2. to \< 12 months.
  3. Primary moderate to severe valvular disease (except for functional mitral valve regurgitation or tricuspid valve regurgitation)
  4. Mechanical tricuspid valve replacement
  5. Severe chronic kidney disease (estimated ≤ 15 ml/1,73 m2 or receiving renal replacement treatment including hemodialysis or peritoneal dialysis)
  6. Obstructive hypertrophic cardiomyopathy
  7. Infiltrative cardiomyopathy (amyloidosis, sarcoidosis, Fabry disease, others)
  8. Acute coronary syndrome or coronary revascularization (CABG or PCI) \<3 months
  9. Severe primary pulmonary disease such as cor pulmonale, irreversible lung disease requiring inhalers, oxygen supplementation
  10. Pacemaker/ICD/CRT treatment ongoing, or current pacemaker indication
  11. Simultaneous participation in a different randomized clinical trial
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    LBBAP+AVNA arm

    Left bundle branch area pacing combined with atrioventricular node ablation.

    Procedure: Pacemaker implantation with Left bundle branch area pacing (LBBAP) · Procedure: Atrioventricular node ablation (AVNA)

  • Sham comparator
    Control arm

    Pharmacologic treatment optimized according to guidelines in patients with permanent atrial fibrillation refractory or intolerant to drug therapy or catheter ablation.

    Drug: Pharmacologic therapy optimized for Atrial Fibrillation management

Interventions

  • ProcedurePacemaker implantation with Left bundle branch area pacing (LBBAP)

    Left bundle branch pacing is a novel pacing modality that can bypass the pathological or disease-vulnerable region in the cardiac conduction system, to provide physiological pacing modality for patients. The procedure involves the implantation of a permanent pacemaker with a pacing lead positioned at the left bundle branch area to achieve physiological conduction system pacing. LBBAP-Pacemaker device and leads should be implanted according to the physician's standard practice.

  • ProcedureAtrioventricular node ablation (AVNA)

    Atrioventricular node ablation uses heat energy, called radiofrequency energy, to destroy the area between the upper and lower heart chambers. This area is called the atrioventricular node.

  • DrugPharmacologic therapy optimized for Atrial Fibrillation management

    Pharmacologic therapy includes rate control with beta-blockers (e.g., bisoprolol), calcium channel blockers (e.g., diltiazem), or antiarrhythmic drugs (e.g., flecainide, propafenone, dronedarone, amiodarone) along with anticoagulation therapy (e.g., apixaban) as per current clinical guidelines (e.g., ESC 2024 or ACC/AHA/HRS 2023) in patients with permanent atrial fibrillation refractory or intolerant to drug therapy or catheter ablation. Treatment is tailored based on patient tolerance and clinical efficacy.

06

What researchers measure

Primary outcomes

  1. Change in NT-proBNP concentration (pg/ml) from baseline to 6-month follow-up

    Time frame: 6 months after intervention.

Secondary outcomes

  1. Change in NT-proBNP concentration (pg/ml) at 12, and 24 months

    Time frame: 12 months and 24 months after intervention.

  2. Change in health-related quality of life measured by 36-item short form survey (SF-36) questionnaire at 6, 12, 24 months

    The SF-36 is a 36-item questionnaire that measures health-related quality of life across eight domains, including physical functioning, bodily pain, and mental health. Scores range from 0 to 100, with higher scores indicating better health-related quality of life.

    Time frame: 6, 12 and 24 months after intervention.

  3. Change in health-related quality of life measured by EuroQol 5-Dimension Questionnaire (EQ-5D) at 6, 12, 24 months

    The EuroQol 5-Dimension Questionnaire (EQ-5D) evaluates health-related quality of life using a descriptive system with five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Scores are derived as an index value (range: -0.594 to 1) The value attached to an EQ-5D profile according to a set of weights that reflect, on average, people's preferences about how good or bad the state is. Values are anchored at 1 (full health) and 0 (a state as bad as being dead) as required by their use in economic evaluation. Values less than 0 represent health states regarded as worse than a state that is as bad as being dead. An EQ-5D value is also sometimes known as an 'index', 'score' or 'utility'

    Time frame: 6, 12 and 24 months after intervention.

  4. Change in left ventricular ejection fraction (LV-EF, %) at 6, 12, and 24 months

    Time frame: 6, 12 and 24 months after intervention

  5. Change in left ventricular end-diastolic diameter (LVEDD, mm) at 6, 12, and 24 months

    Time frame: 6, 12 and 24 months after intervention.

  6. Change in left ventricular end systolic diameter (LVESD, mm) at 6, 12, and 24 months

    Time frame: 6, 12 and 24 months after intervention.

  7. Change in New York Heart Association (NYHA) functional class at 6, 12, and 24 months

    The NYHA functional classification system assesses the severity of heart failure symptoms on a scale from Class I (best) to Class IV (worst). Changes in functional class will be evaluated at 6, 12, and 24 months after the intervention to determine the impact on patients' physical activity and symptom burden.

    Time frame: 6, 12 and 24 months after intervention.

  8. Change in 6 min walk test at 6, 12, and 24 months

    Time frame: 6, 12, and 24 months after intervention

  9. Change in cognitive function measured by Montreal Cognitive Assessment (MoCA) score at 6, 12, and 24 months

    The Montreal Cognitive Assessment (MoCA) is a widely used cognitive screening tool that assesses various cognitive domains, including memory, attention, language, visuospatial skills, and executive function. The MoCA score ranges from 0 to 30, with higher scores indicating better cognitive function. A score of 26 or above is generally considered normal, while lower scores suggest cognitive impairment. Changes in MoCA scores will be evaluated at 6, 12, and 24 months post-intervention.

    Time frame: 6, 12 and 24 months after intervention.

  10. Procedure-related complications (tamponade, device infection, re-intervention, pneumothorax, vascular complications, others)

    Time frame: 24 months after intervention.

  11. The all-cause mortality at 24 months

    Death from any cause during the 24-month follow-up period.

    Time frame: 24 months after intervention.

  12. Worsening Heart Failure (HF) at 24 Months

    \*Worsening HF with or without hospitalization: symptoms, signs, imaging, and analytical criteria that require unplanned medical attention with an increase of diuretic use, intravenous diuretic therapy

    Time frame: 24 months after intervention.

  13. Composite Outcome: Mortality and worsening heart failure (HF) at 24 months

    Participants meeting at least one of the criteria: (a) all-cause mortality, (b) worsening heart failure.

    Time frame: 24 months after intervention.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 35 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2024
First posted
Nov 21, 2024
StartActual
Jan 27, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06699342
Responsible party
Eue-Keun Choi (Professor, Seoul National University Hospital) — Principal investigator
First posted
Nov 21, 2024
Start date
Jan 27, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

Eue-keun Choi, M.D. Ph.D
Contact
choiek417@gmail.com
82-2-2072-0688

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion